SADIA EJAZ
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism CHAPEL HILL, NC NPI 1922481977
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism NC Lilly USA, LLC All categories
General Payments — all program years on this page
$14,244.06
- Category: General Payments
- Program years: PY2018–2024
- Record count: 815
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $3,472.06 across 184 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $3,472.06 | 184 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $602.38 | 36 |
| Abbott Laboratories | $588.92 | 30 |
| Novo Nordisk AS | $402.44 | 26 |
| Corcept Therapeutics | $347.21 | 13 |
| Antares Pharma, Inc. | $240.95 | 10 |
| Amgen Inc. | $224.01 | 14 |
| ABBVIE INC. | $117.81 | 7 |
| DEXCOM, INC. | $117.09 | 6 |
| Bayer HealthCare Pharmaceuticals Inc. | $100.16 | 5 |
| MannKind Corporation | $89.11 | 5 |
| Radius Health, Inc. | $71.84 | 3 |
| Medtronic, Inc. | $64.44 | 4 |
| VIVUS LLC | $48.79 | 3 |
| SANOFI-AVENTIS U.S. LLC | $46.46 | 3 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $44.64 | 2 |
| CeQur Corporation | $44.43 | 1 |
| Xeris Pharmaceuticals, Inc. | $39.17 | 2 |
| BETA BIONICS, INC. | $32.44 | 1 |
| Esperion Therapeutics, Inc. | $28.49 | 2 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $28.04 | 2 |
| Kyowa Kirin, Inc. | $26.12 | 1 |
| Insulet Corporation | $24.55 | 1 |
| Alexion Pharmaceuticals, Inc. | $23.72 | 1 |
| Nevro Corp. | $22.95 | 1 |
| IBSA Pharma Inc. | $21.41 | 1 |
| RECORDATI_RARE_DISEASES_INC. | $21.38 | 1 |
| Tandem Diabetes Care, Inc. | $20.06 | 1 |
| Amneal Pharmaceuticals LLC | $17.58 | 1 |
| Astellas Pharma US Inc | $15.47 | 1 |
By program year
Records — PY2024 (184)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.